Government passes off factually incorrect vaccination information as ‘fact’
According to the PIB release, the myth was that the Centre wasn’t taking any step to vaccinate children. Clarifying this, Dr. Paul said: “As of now, no country in the…
Category: Emergency use authorisation
India sets a dangerous precedent with COVID-19 vaccination programme
A large percentage of those aged 18-44 years does not have the resources to pay for vaccines and hence will fall through the cracks. So, the States will have to…
Should Covaxin trial continue till 130 cases are recorded?
According to details posted on the clinical trial registry, the company had planned to “continue the phase-3 trial until 130 study participants developed PCR-confirmed symptomatic COVID-19 disease during follow-up beginning…
Covaxin should no longer be available in ‘clinical trial mode’
The vaccine efficacy was measured based on symptomatic COVID-19 disease — mild, moderate or severe — two weeks after the second dose. The interim analysis undertaken at the first endpoint…
Pfizer vaccine can be stored at -15 to -25 degree C for two weeks
On December 11, 2020 when the U.S. FDA approved the vaccine for emergency use, the storage temperature stipulated was -60 to -80 degree C. The labels for the vaccine too…
Indian scientists divided over restricted use approval for Covaxin
In a tweet on January 14, the Health Ministry said both Covishield and Covaxin approved for restricted use by the Indian regulator are safe. The Health Ministry released a statement…
Vaccine dilemma: To take or not to take Covaxin
True, in the U.S., vaccines from both Pfizer and Moderna are available and recipients, who are health-care workers and nursing home residents, have no option to choose the vaccine. In…
Can COVID-19 vaccines with EUA be used at the population level?
Meanwhile, the Indian government has spelt out four high-risk groups — healthcare workers, frontline workers, those over 50 years of age and those aged below 50 years but with co-morbidities…
